Comparison Results | RestoredCDC.org

Comparison timestamp: 2025-05-14 04:20:53 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/diabetes/data-research/research/new-diabetes-medicines.html
Live cdc.gov URL ↗: https://www.cdc.gov/diabetes/data-research/research/new-diabetes-medicines.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected: Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Enable word-level highlighting (experimental)? High contrast mode
    Original site: www.cdc.gov/diabetes/data-research/research/new-diabetes-medicines.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
    [More]
    About Us Report Bug Compare Content
  Skip directly to site content Skip directly to search Skip directly to On This Page
          An official website of the United States government
        Here's how you know
              Official websites use .gov
              A .gov website belongs to an official government organization in the United States.
              Secure .gov websites use HTTPS
              A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
        Diabetes
          Explore Topics
        Search
          Search
          Clear Input
        For Everyone
          * Basics
          * Symptoms
          * Testing
          * Risk Factors
          * Preventing
          * Treatment
          * Providing Care
          * Living with Diabetes
          * View all
        Health Care Providers
          * Clinical Guidance
          * DSMES for Health Care Providers
          * Prevent Type 2 Diabetes: Talking to Your Patients About Lifestyle Change
          * Employers and Insurers
          * View all
        Public Health
          * Community-based Organizations (CBOs)
          * Toolkits for Diabetes Educators and Community Health Workers
          * National Diabetes Statistics Report
          * Reports and Publications
          * Data and Statistics
          * Current Research Projects
          * View all
          Related Topics:
            National Diabetes Prevention Program | State, Local, and National Partner Diabetes Programs for Public Health | Diabetes Self-Management Education and Support (DSMES) Toolkit | About the Division of Diabetes Translation
        View All
      search close search
          search
    Diabetes Menu Close
    Diabetes Menu
          search
              For Everyone
                  * Basics
                  * Symptoms
                  * Testing
                  * Risk Factors
                  * Preventing
                  * Treatment
                  * Providing Care
                  * Living with Diabetes
                  * View All Home
              Health Care Providers
                  * Clinical Guidance
                  * DSMES for Health Care Providers
                  * Prevent Type 2 Diabetes: Talking to Your Patients About Lifestyle Change
                  * Employers and Insurers
                  * View All
              Public Health
                  * Community-based Organizations (CBOs)
                  * Toolkits for Diabetes Educators and Community Health Workers
                  * National Diabetes Statistics Report
                  * Reports and Publications
                  * Data and Statistics
                  * Current Research Projects
                  * View All
              Related Topics
                  * National Diabetes Prevention Program
                  * State, Local, and National Partner Diabetes Programs for Public Health
                  * Diabetes Self-Management Education and Support (DSMES) Toolkit
                  * About the Division of Diabetes Translation
        View All Diabetes
    Basics Symptoms Testing Risk Factors Preventing Treatment Providing Care Living with Diabetes View All
May 15, 2024
  Use of New Diabetes Medicines
          Key points
            * Recent guidelines from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend newer types of diabetes medications.
            * CDC researchers found that most Americans living with type 2 diabetes are eligible under these new guidelines.
        What did this study examine?
        In 2022, the ADA and EASD jointly released new medication recommendations for adults with type 2 diabetes. They recommended newer types of diabetes medications as first-line (first recommended) treatment for adults with type 2 diabetes who also have:
          * A heart disease called atherosclerotic cardiovascular disease (ASCVD).
          * Heart failure.
          * Kidney disease.
          * High risk for ASCVD.
        This study examined how many US adults with type 2 diabetes would meet the recommended criteria to use these medications.
        Terms to know
        Glucagon-like peptide-1 receptor agonists, or GLP-1s, are a type of medicine for people with diabetes. They lower blood sugar levels, can help with weight loss, and protect the heart and kidneys.
        Sodium-glucose cotransporter-2 inhibitors, or SGLT-2s are a type of medicine for people with diabetes. Similar to GLP-1s, they lower blood sugar levels, can help with weight loss, and protect the heart and kidneys. Because GLP-1s and SGLT-2s work in different ways, they can be taken together.
        Atherosclerotic cardiovascular disease, also known as ASCVD, is a type of heart disease where blood vessels are narrowed or damaged. People at high risk of ASCVD were defined as being over age 55 and having 2 or more risk factors:
          * Obesity
          * Hypertension
          * High cholesterol
          * Kidney disease
          * Current smoking
        Study results
        CDC researchers studied 1,330 nonpregnant adults with type 2 diabetes between 2017 and 2020.
        Researchers estimate that with new ADA and EASD guidelines, 82% of US adults with type 2 diabetes may be eligible to take a GLP-1, or SGLT-2, or both. They also estimate that almost all Medicare beneficiaries with type 2 diabetes may be eligible to take these medicines.
        Very few US adults were taking GLP-1s or SGLT-2s during the study timeframe (2017-2020). This is because they were not yet approved for first-line treatment. Only 9% were already taking either a GLP-1 or an SGLT-2 medication.
        What's important about this study?
        This study showed that over 8 in 10 US adults with type 2 diabetes are eligible for new, effective diabetes medicines.
        These medicines are not just beneficial for blood sugar management. They also help reduce risk for diabetes complications by protecting the heart and kidneys, and help people lose weight if needed.
        Currently, these medicines are expensive, and cost may be a barrier for many people with type 2 diabetes. More research on cost-effectiveness can help guide diabetes interventions at a sustainable cost.
          See Also: Access the full article
        On This Page
            * What did this study examine?
            * Study results
            * What's important about this study?
          Related PagesResearch Summaries
          Related Pages
        * 
 
            * Research Summaries
            * Cost of Diabetes Complications for Medicare Beneficiaries
            * Diabetes in Young People Is on the Rise
        * 
            * Additional 12 Million US Adults Eligible for Diabetes Screening
            * Trends in Diabetes Among Young People
        * 
            * Kidney Failure and Diabetes
        * View All
          View All Diabetes
 
    Kidney Failure and Diabetes
        Back to Top
  May 15, 2024
  May 14, 2024
      Sources Print Share
        Facebook LinkedIn Twitter Syndicate
          Content Source:
        National Center for Chronic Disease Prevention and Health Promotion; Diabetes
        Sources
          * Tang, S., Shao, H., Ali, M. K., & Zhang, P. (2023). Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Annals of Internal Medicine.
      Related PagesResearch Summaries
      Related Pages
    * 
 
        * Research Summaries
        * Cost of Diabetes Complications for Medicare Beneficiaries
        * Diabetes in Young People Is on the Rise
    * 
        * Additional 12 Million US Adults Eligible for Diabetes Screening
        * Trends in Diabetes Among Young People
    * 
        * Kidney Failure and Diabetes
    * View All
      View All Diabetes
  Back to Top
    Diabetes
    Diabetes is a chronic disease that affects how your body turns food into energy. About 1 in 10 Americans has diabetes.
    View All
        For Everyone
          * Basics
          * Symptoms
          * Testing
          * Risk Factors
          * Preventing
          * Treatment
          * Providing Care
          * Living with Diabetes
          * View all
          Health Care Providers
            * Clinical Guidance
            * DSMES for Health Care Providers
            * Prevent Type 2 Diabetes: Talking to Your Patients About Lifestyle Change
            * View All
          Public Health
            * Community-based Organizations (CBOs)
            * Toolkits for Diabetes Educators and Community Health Workers
            * National Diabetes Statistics Report
            * View All
        Sign up for Email Updates
    Contact Us
        Contact Us
          * Call 800-232-4636
          * Contact CDC
    About CDC
        About CDC
          * Pressroom
          * Organization
          * Budget & Funding
          * Careers & Jobs
    Policies
              * Accessibility
              * External Links
              * Privacy
              * Web Policies
              * FOIA
              * OIG
              * No Fear Act
              * Nondiscrimination
              * Vulnerability Disclosure Policy
    Languages
            Languages
              * Español
            Language Assistance
                  * Español
                  * 繁體中文
                  * Tiếng Việt
                  * 한국어
                  * Tagalog
                  * Русский
                  * العربية
                  * Kreyòl Ayisyen
                  * Français
                  * Polski
                  * Português
                  * Italiano
                  * Deutsch
                  * 日本語
                  * فارسی
                  * English
    Archive
          * CDC Archive
          * Public Health Publications
    Contact Us
      Contact Us
        * Call 800-232-4636
        * Contact CDC
    About CDC
        * Pressroom
        * Organization
        * Budget & Funding
        * Careers & Jobs
        * About CDC
    Policies
        * Accessibility
        * External Links
        * Privacy
        * Web Policies
        * FOIA
        * OIG
        * No Fear Act
        * Nondiscrimination
        * Vulnerability Disclosure Policy
    Languages
      Languages
        * Español
      Language Assistance
        * Español
        * 繁體中文
        * Tiếng Việt
        * 한국어
        * Tagalog
        * Русский
        * العربية
        * Kreyòl Ayisyen
        * Français
        * Polski
        * Português
        * Italiano
        * Deutsch
        * 日本語
        * فارسی
        * English
    Archive
        * CDC Archive
        * Public Health Publications
    HHS.gov USA.gov
Note: Comparison ignores leading/trailing whitespace and certain script/tracking codes. Word-level highlighting (optional above) only applies to changed lines.